Ovarian Cancer Genetic Test: Understanding Your Hereditary Risk

Introduction

Ovarian cancer is one of the most serious gynaecological cancers affecting women worldwide. It often develops silently, with vague symptoms that can easily be mistaken for minor health issues, which is why it is frequently diagnosed at a later stage. Early detection plays a crucial role in improving survival rates and treatment outcomes. In recent years, advances in genetics have transformed our understanding of cancer development, particularly in ovarian cancer. Through an Ovarian Cancer Genetic Test, doctors can identify inherited gene mutations—such as BRCA1 and BRCA2—that significantly increase a woman’s risk. This knowledge allows for personalised prevention strategies, regular monitoring, and, in some cases, life-saving early interventions.

Genes Linked to Ovarian Cancer

Several genes have been identified as critical contributors to the development of ovarian cancer, with the most well-known being BRCA1, BRCA2, RAD51C, RAD51D, MLH1, and MSH2. Each of these genes plays a vital role in maintaining the integrity of our DNA and regulating normal cell growth.

• BRCA1 and BRCA2: These are tumour suppressor genes that help repair damaged DNA and prevent abnormal cell division. Mutations in these genes significantly increase a woman’s lifetime risk of ovarian and breast cancers, with BRCA1 mutations linked to a risk of up to 46% for ovarian cancer, and BRCA2 mutations associated with a risk of around 12–20%.

• RAD51C and RAD51D: These genes are also involved in DNA repair through a process called homologous recombination. Mutations can compromise DNA repair mechanisms, making cells more prone to becoming cancerous.

• MLH1 and MSH2: These genes are part of the DNA mismatch repair system, which corrects errors during DNA replication. Mutations in these genes are associated with Lynch syndrome, which increases the risk of several cancers, including ovarian and colorectal cancers.

Mutations in these genes interfere with the cell’s ability to repair DNA damage effectively. When DNA damage accumulates, cells can start to grow uncontrollably, forming tumours. Detecting these mutations through an Ovarian Cancer Genetic Test allows doctors to identify individuals at high risk and implement early monitoring or preventive strategies.

It is essential to distinguish between inherited (germline) mutations and acquired (somatic) mutations:

• Inherited mutations are passed down from parents to children and are present in every cell of the body. They indicate a lifelong predisposition to cancer and can have implications for other family members.

• Acquired mutations, on the other hand, occur spontaneously in certain cells during a person’s lifetime and are not inherited. These mutations can lead to cancer in the affected cells but do not increase the risk for relatives.

Understanding which type of mutation is present helps clinicians make informed decisions about risk assessment, preventive measures, and treatment options, ultimately improving outcomes for those at risk of ovarian cancer.

Who Should Consider Ovarian Cancer Genetic Testing?

Genetic testing for ovarian cancer is particularly important for high-risk groups. Identifying individuals in these groups enables early intervention, personalised preventive strategies, and informed decision-making.

Hover over each box for more detailed information!

Family History of Ovarian or Breast Cancer

Increased risk if first-degree relatives have cancer.

Women with one or more first-degree relatives (mother, sister, daughter) diagnosed with ovarian or breast cancer have a higher likelihood of carrying hereditary mutations such as BRCA1 or BRCA2. Genetic testing helps assess this risk and guide personal risk management and family planning.

Known Gene Mutations in Relatives

Testing is recommended even if relatives have not developed cancer.

If a first-degree relative carries a confirmed gene mutation, testing is advised. Early identification allows preventive measures such as regular screenings, lifestyle modifications, or prophylactic surgery to reduce cancer risk.

Patients Already Diagnosed with Cancer

Guides treatment decisions and informs family risk.

Women diagnosed with ovarian or related cancers (e.g., breast cancer) may undergo genetic testing to inform therapy choices. Certain gene mutations can increase tumour responsiveness to targeted treatments like PARP inhibitors and indicate hereditary risk for relatives.

Targeted testing for high-risk groups. Focusing on these populations ensures early detection, personalised preventive strategies, and informed decision-making. Genetic counselling is recommended before and after testing to fully understand the implications for patients and their families.

How the Test Is Done

An Ovarian Cancer Genetic Test is a straightforward procedure that involves analysing a sample of a person’s DNA to detect inherited mutations associated with ovarian cancer risk. The process generally begins with sample collection, which can be performed using one of several non-invasive methods:

• Blood sample: A small vial of blood is drawn from a vein, usually in the arm, which contains cells suitable for DNA analysis.

• Saliva sample: The patient provides a saliva specimen, which also contains DNA for testing.

• Buccal (cheek) cells: A swab is rubbed against the inside of the cheek to collect cells for genetic analysis.

Once the sample is collected, it is sent to a specialised laboratory. In the lab, technicians extract DNA from the cells and examine specific genes known to be linked to ovarian cancer, such as BRCA1, BRCA2, RAD51C, RAD51D, MLH1, and MSH2. Advanced sequencing technologies and bioinformatics tools are used to detect mutations and determine whether they are inherited or acquired.

The time required to receive results can vary depending on the laboratory and the complexity of the test. Typically, results are available within 2 to 6 weeks. Once the results are ready, a healthcare professional or genetic counsellor will review them with the patient, explain their implications, and discuss any recommended follow-up actions, preventive strategies, or treatment options if a mutation is identified.

Overall, while the testing process itself is simple and minimally invasive, the insights gained from an Ovarian Cancer Genetic Test can be life-changing, guiding personalised care and early interventions.

Interpreting the Results of an Ovarian Cancer Genetic Test

Once an Ovarian Cancer Genetic Test has been completed, understanding the results is a crucial step in determining next actions and managing cancer risk. Test outcomes generally fall into three categories:

1. Positive result:
   A positive result indicates that a pathogenic mutation has been detected in one of the genes associated with ovarian cancer, such as BRCA1 or BRCA2. This means the individual has a significantly increased risk of developing ovarian cancer and may also be at risk for other related cancers. A positive result can inform personalised monitoring, preventive strategies, and, in some cases, surgical or pharmacological interventions.

2. Negative result:
   A negative result suggests that no known pathogenic mutations were found in the tested genes. While this reduces the likelihood of a hereditary predisposition, it does not eliminate the possibility of developing ovarian cancer entirely. Environmental factors, lifestyle, and other non-tested genetic factors may still contribute to risk.

3. Variant of Uncertain Significance (VUS):
   Sometimes, the test identifies a genetic change whose impact on cancer risk is not yet clearly understood. This is known as a Variant of Uncertain Significance (VUS). Individuals with a VUS should not make major medical decisions based solely on this result. Instead, ongoing research and periodic re-evaluation of the variant’s classification are recommended.

Genetic counselling is an essential part of interpreting results. A trained genetic counsellor or healthcare professional will:

• Explain what the results mean for the patient’s personal cancer risk.

• Discuss potential implications for family members.

• Recommend appropriate follow-up measures, such as increased surveillance, preventive medication, or risk-reducing surgery if indicated.

• Provide psychological support to help patients cope with the emotional impact of the results.

By understanding and acting on the results of an Ovarian Cancer Genetic Test, patients and their healthcare teams can make informed, proactive decisions to reduce cancer risk and improve long-term outcomes.

Benefits of an Ovarian Cancer Genetic Test

An Ovarian Cancer Genetic Test offers several significant benefits, particularly for individuals at increased risk or for those already diagnosed with cancer. Understanding these advantages can help patients make informed decisions about their health and take proactive steps to reduce cancer risk.

1. Enabling prevention for high-risk individuals:
   For women who carry mutations in genes such as BRCA1 or BRCA2, genetic testing provides critical information about their elevated risk of developing ovarian cancer. With this knowledge, healthcare providers can recommend preventive measures, which may include lifestyle adjustments, chemoprevention, or, in certain cases, prophylactic surgery to remove the ovaries before cancer develops. This proactive approach can dramatically reduce the likelihood of cancer occurring.

2. Planning for early detection and monitoring:
   An Ovarian Cancer Genetic Test allows doctors to create a personalised surveillance plan for high-risk patients. Regular screenings, including pelvic ultrasounds and blood tests for tumour markers such as CA-125, can be scheduled at more frequent intervals. Early detection is crucial, as ovarian cancer diagnosed at an early stage has a significantly higher chance of successful treatment and improved survival rates.

3. Guiding targeted treatment for patients with cancer:
   For individuals already diagnosed with ovarian cancer, genetic testing can inform treatment decisions. Certain gene mutations make tumours more responsive to specific therapies, such as PARP inhibitors. By understanding the genetic profile of the patient, doctors can tailor treatment plans that are more effective, minimise unnecessary side effects, and improve overall outcomes.

In summary, an Ovarian Cancer Genetic Test not only provides essential information for risk reduction and early detection but also plays a pivotal role in guiding personalised treatment. These benefits make genetic testing an invaluable tool in both preventive and clinical care for ovarian cancer.

Preventive and Management Options for High-Risk Women Identified by an Ovarian Cancer Genetic Test

For women identified as high-risk through an Ovarian Cancer Genetic Test, several preventive and management strategies can significantly reduce the likelihood of developing ovarian cancer and improve overall health outcomes.

1. Regular monitoring (Screening):
   High-risk individuals are advised to undergo frequent surveillance, including pelvic ultrasounds and blood tests for tumour markers such as CA-125. While screening cannot prevent cancer, it facilitates early detection when the disease is most treatable, greatly improving survival chances.

2. Preventive medications:
   In some cases, healthcare providers may recommend medications that can lower the risk of ovarian cancer. For example, certain hormonal treatments or oral contraceptives have been shown to reduce ovarian cancer risk in high-risk populations. These pharmacological approaches are usually combined with regular monitoring to maximise protective effects.

3. Prophylactic surgery (Oophorectomy):
   Women with particularly high-risk gene mutations, such as BRCA1 or BRCA2, may consider preventive removal of the ovaries and fallopian tubes (bilateral salpingo-oophorectomy). This surgery can reduce the risk of ovarian cancer by over 90% and is typically recommended after childbearing is complete. Pre-surgical counselling and a discussion of potential side effects, including early menopause, are essential.

4. Lifestyle and nutrition:
   Although lifestyle cannot change inherited genetic risk, adopting healthy habits can help overall cancer prevention and general well-being. Recommendations include:

   • Maintaining a balanced diet rich in fruits, vegetables, and whole grains

   • Regular physical activity

   • Avoiding smoking and limiting alcohol consumption

   • Managing body weight

Combining these strategies allows high-risk women to take proactive steps, reducing their likelihood of developing ovarian cancer while enhancing overall health and quality of life. The guidance from an Ovarian Cancer Genetic Test ensures that these preventive measures are personalised and evidence-based.